| Literature DB >> 24314122 |
Veeresh K Patil1, John W Holloway, Hongmei Zhang, Nelis Soto-Ramirez, Susan Ewart, S Hasan Arshad, Wilfried Karmaus.
Abstract
BACKGROUND: Asthma is characterized by airflow limitation and airway reactivity (AR). Interleukin-13 (IL-13) is involved in the pathogenesis of asthma. Two functional SNPs, rs20541 and rs1800925, of the IL-13 gene (IL13) have been frequently associated with asthma-related lung functions. However, genetic variation alone does not fully explain asthma risk. DNA-methylation (DNA-M) is an epigenetic mechanism that regulates gene expression and can be influenced by both environment and genetic variants. To explore the interplay of prenatal maternal smoking, genetic variants and DNA-M, we used a two-stage model: (1) identifying cytosine phosphate guanine (CpG) sites where DNA-M is influenced by the interaction between genetic variants and maternal smoking during pregnancy (conditional methQTL (methylation quantitative trait loci)); and (2) determining the effect of the interaction between DNA-M of CpG (from stage 1) and SNPs (modifying genetic variants; modGV) on airflow limitation and AR in 245 female participants of the Isle of Wight birth cohort. DNA-M was assessed using the Illumina Infinium HumanMethylation450 BeadChip.Entities:
Year: 2013 PMID: 24314122 PMCID: PMC3892084 DOI: 10.1186/1868-7083-5-22
Source DB: PubMed Journal: Clin Epigenetics ISSN: 1868-7075 Impact factor: 6.551
Figure 1Two-stage model to investigate environment, SNP and DNA methylation interactions influencing asthma-related lung functions (Modified from Karmaus et al. [16]. CpG, cytosine phosphate guanine; methQTL, methylation, quantitative trait loci (genetic variants that change the susceptibility for DNA methylation); modGV, modifiable genetic variants (genetic variants that are modified by DNA methylation).
Location, position and description of rs1800925, rs20541 and CpG sites on the promoter region of gene
| rs1800925 | 5:131992809 | 5′ Promoter upstream | TT | 8 (3.4%) | |
| CT | 68 (28.8%) | ||||
| CC | 158 (67.8%) | ||||
| rs20541 | 5:131995964 | Exon 4 | AA | 10 (4.3%) | |
| AG | 66 (28.1%) | ||||
| GG | 159 (67.7%) | ||||
| | | ||||
| cg13566430 | 5:131992455 | TSS1500 | 0.18 | 0.14 | 0.23 |
| cg04303330 | 5: 131992430 | TSS1500 | 0.30 | 0.23 | 0.36 |
| cg06584121 | 5: 131993818 | TSS200 | 0.80 | 0.730 | 0.84 |
| cg06967316 | 5: 131993853 | TSS200 | 0.74 | 0.66 | 0.80 |
| cg14523284 | 5: 131993614 | TSS1500 | 0.86 | 0.83 | 0.89 |
| cg15329179 | 5: 131993728 | TSS200 | 0.87 | 0.81 | 0.90 |
CpG, cytosine phosphate guanine; TSS200, 200 base pairs from transcription start site; TSS1500, 1500 base pairs from transcription start site.
Figure 2Whisker plot showing rs1800925 genotype-dependant DNA methylation of cg13566430.
Interaction of methylation at cg13566430 and rs1800925 genotypes on FEV /FVC and DRS
| | | ||||||
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| | 0.175 | −0.166 to 0.517 | 0.313 | −0.568 | −2.361 to 1.226 | 0.533 | |
| 0.020 | −0.024 to 0.064 | 0.369 | −0.075 | −0.278 to 0.129 | 0.469 | ||
| | 0.006 | −0.014 to 0.026 | 0.548 | 0.036 | −0.076 to 0.149 | 0.523 | |
| | | Reference | | | Reference | | |
| 0.030 | −0.019 to 0.079 | 0.231 | 0.299 | 0.045 to 0.554 | 0.021 | ||
| | −0.001 | −0.021 to 0.019 | −0.001 | −0.026 | −0.134 to 0.083 | 0.644 | |
| | | Reference | | | Reference | | |
| | | | | | | | |
| −0.412 | −0.855 to 0.030 | 0.068 | 3.989 | 1.194 to 6.785 | 0.005 | ||
| | −0.134 | −0.296 to 0.028 | 0.106 | 0.124 | −0.733 to 0.982 | 0.775 | |
| | | Reference | | | Reference | | |
| | 0.174 | −0.301 to 0.648 | 0.472 | 0.624 | −1.926 to 3.174 | 0.629 | |
| 3.274 | 0.114 to 6.434 | 0.042 | −27.497 | −48.283 to −6.710 | 0.010 | ||
| | 0.799 | −0.114 to 1.712 | 0.086 | −0.809 | −5.661 to 4.043 | 0.742 | |
| Reference | Reference | ||||||
DRS, dose response slope; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Figure 3Graph showing interaction of rs1800925 and methylation at cg13566430 influencing FEV/FVC. FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.